Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

GeneQuantum Completes C Round for Novel ADC Candidates

publication date: May 20, 2021

GeneQuantum Healthcare (Suzhou) completed a Series C funding to develop its portfolio of site-specific antibody drug conjugate molecules. According to the company, the C round raised several hundreds of millions of RMB, which puts the funding at least in the $50 million range, but the exact amount was not disclosed. GeneQuantum says it has built a differentiated ADC platform that addresses the major problems of ADC drugs: high heterogeneity, narrow therapeutic window and high manufacturing cost. The Series C was led by China Life Private Equity Investment. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital